Crucial Role of Phospholipase Cε in Chemical Carcinogen-Induced Skin Tumor Development

Yunfeng Bai, Hironori Edamatsu, Sakan Maeda, Hiromitsu Saito, Noboru Suzuki, Takaya Satoh, and Tohru Kataoka

Abstract

Mutational activation of the ras proto-oncogenes is frequently found in skin cancers. However, the nature of downstream signaling pathways from Ras involved in skin carcinogenesis remains poorly understood. Recently, we and others identified phospholipase Cε (PLCε) as an effector of Ras. Here we have examined the role of PLCε in de novo skin chemical carcinogenesis by using mice whose PLCε is genetically inactivated. PLCε−/− mice exhibit delayed onset and markedly reduced incidence of skin squamous tumors induced by initiation with 7,12-dimethylbenz(a)anthracene followed by promotion with 12-O-tetradecanoylphorbol-13-acetate (TPA). Furthermore, the papillomas formed in PLCε−/− mice fail to undergo malignant progression into carcinomas, in contrast to a malignant conversion rate of approximately 20% observed with papillomas in PLCε+/− mice. In all of the tumors analyzed, the Ha-ras gene is mutationaly activated irrespective of the PLCε background. The skin of PLCε−/− mice exhibits to fail basal layer cell proliferation and epidermal hyperplasia in response to TPA treatment. These results indicate a crucial role of PLCε in ras oncogene-induced de novo carcinogenesis and downstream signaling from TPA, introducing PLCε as a candidate molecular target for the development of anticancer drugs.

Introduction

The ras proto-oncogenes are mutationaly activated in about 15% of human neoplasms (1). Their products, Ras small GTPases, control cell proliferation and differentiation through interaction with multiple effector proteins, among which Raf kinases have been implicated in carcinogenesis from studies on in vitro transformation of fibroblast cell lines (2) and on genomic mutations in malignant melanoma (3). However, downstream signaling pathways from Ras involved in epithelial cell carcinogenesis remain poorly understood, despite the fact that ras mutations are more frequently found in epithelial cell-derived neoplasms (1). Likewise, the role of phosphoinositide-specific phospholipase C (PLC) in carcinogenesis remains obscure (4). PLC expresses two vital intracellular second messengers, diacylglycerol and inositol 1,4,5-trisphosphate, which induce activation of protein kinase C and mobilization of Ca2+, respectively. Among 12 mammalian PLC isoforms classified into 5 classes (4), PLCε is characterized by possession of the Ras-associated domains, which are responsible for PLCε activation through direct association with the GTP-bound active forms of the small GTPases Ras (5, 6), Rap1 (7), and Rap2 (8). PLCε was also reported to be regulated by α1c, α1f, and β1γ2 subunits of heterotrimeric G proteins and Rho small GTPase (9). Identification of PLCε as a Ras effector has prompted us to examine the role of PLCε in carcinogenesis. Here we show that PLCε-deficient mice are resistant to chemical carcinogen-induced skin tumor formation, suggesting a crucial role of PLCε in tumor development downstream of Ras signaling.

Materials and Methods

PLCε−/− Mice. Targeted inactivation of the PLCε gene was performed by a standard embryonic stem cell-based method. The targeted allele (PLCε−/−) expresses a mutant PLCε with an in-frame deletion of amino acids 1333 to 1408 corresponding to the NH2-terminal part of the catalytic X domain. This mutant completely lost its PLC catalytic activity. PLCε−/− mice were maintained on a mixed 129/Sv × C57BL/6 background.

Reverse Transcription-Polymerase Chain Reaction Analysis. Reverse transcription-polymerase chain reaction (RT-PCR) was performed as described previously (10). Primers used for amplification of PLCε were 5′-TCAGTGCTCTGAGACACGACAG-3′ and 5′-CTTGAAAGGGATCTTCGTTG-3′.

Skin Tumor Formation. A dorsal area of skin of 8-week–old mice was shaved and treated with a single application of 7,12-dimethylbenz(a)anthracene [DMBA (25 μg in 100 μL of acetone; Sigma, St. Louis, MO)] and subsequently treated with 12-O-tetradecanoylphorbol-13-acetate [TPA (0.2 mmol/L in 100 μL of acetone; Sigma)] twice a week for 20 weeks (11). Tumors were assessed weekly for up to 30 weeks and defined as raised lesions with a minimum diameter of 1 mm. Values were determined by unpaired Student's t test using GraphPad InStat software (GraphPad Software, Inc., San Diego, CA).

Histologic Analysis. Paraffin-embedded sections were prepared and stained with hematoxylin and eosin or with a specific antibody against mouse PLCε (10), keratin 14 (PRB-155P; BABCO, Berkeley, CA), or keratin 1 (PRB-165P; BABCO). Detection of immunoreactive signals was performed with HistoMouse Plus kit (Zymed Laboratories, South San Francisco, CA) or with a fluorescein isothiocyanate-conjugated secondary antibody (AP182F; Chemicon, Temecula, CA).

12-O-Tetradecanoylphorbol-13-acetate–Induced Skin Hyperplasia. A dorsal area of skin of 10-week–old mice was treated with TPA (0.2 mmol/L in 100 μL of acetone). The mouse skin was analyzed by staining with an anti-proliferating cell nuclear antigen (PCNA) antibody (M0879; Dako Cytomation, Copenhagen, Denmark) or hematoxylin and eosin. The thickness of the epidermis was measured at a minimum of five different points on the specimens and averaged.

Analysis of Ha-ras Gene Mutations. Ha-ras gene mutations at the 61st codon of the tumors were analyzed as described previously (12).

Results and Discussion

RT-PCR analysis of skin RNA detected two amplified products whose sizes were identical to those predicted from the wild-type and mutant PLCε mRNAs (Fig. 1A). Immunohistochemical analysis

Received 8/30/04; revised 10/12/04; accepted 10/21/04.

Grant support: Grant-in-Aid for Priority Areas 12215098 (T. Kataoka); Grants-in-Aid for Scientific Research 15570117 (T. Satoh); and 21st Century COE Programs (T. Kataoka and T. Satoh) from the Ministry of Education, Science, Sports and Culture of Japan.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked advertisement in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Requests for reprints: Tohru Kataoka, Division of Molecular Biology, Department of Molecular and Cellular Biology, Kobe University Graduate School of Medicine, 7-5-1 Kusunoki-cho, Chuo-ku, Kobe 650-0017, Japan. E-mail: kataoka@kobe-u.ac.jp.

©2004 American Association for Cancer Research.
showed that PLCε is expressed in the epidermis (Fig. 1B), including keratin 14-positive proliferative keratinocytes and keratin 1-positive differentiating keratinocytes, but not in the dermis, except for hair follicles (Fig. 1C). To address the role of PLCε in de novo skin carcinogenesis, we applied the skin two-stage chemical carcinogenesis protocol (11) on PLCε−/− mice. Initiation was carried out with a single application of DMBA, which almost invariably introduced oncogenic mutations on the Ha-ras gene (11, 12). Subsequent promotion by repeated treatment with TPA for 20 weeks caused the selective clonal outgrowth of the initiated cells to produce benign squamous tumors (Fig. 2A). PLCε−/− mice showed significant delay in the average time of tumor onset compared with PLCε+/+ mice [average ± SE: 12.63 ± 0.42 weeks (PLCε−/−; 21 mice analyzed) versus 10.14 ± 0.47 weeks (PLCε+/+; 14 mice); P < 0.001; Fig. 2B].

<table>
<thead>
<tr>
<th>Table 1 Histological analysis of tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>PLCε genotypes</td>
</tr>
<tr>
<td>Hyperplasias</td>
</tr>
<tr>
<td>Papillomas</td>
</tr>
<tr>
<td>Carcinomas</td>
</tr>
<tr>
<td>Carcinomas/tumors (%)</td>
</tr>
<tr>
<td>Total no. of tumors analyzed</td>
</tr>
</tbody>
</table>

NOTE. n represents the number of mice analyzed.

Fig. 1. Analysis of PLCε expression. A, RT-PCR analysis of PLCε mRNA in the skin. β-Actin mRNA was used as an internal control. B and C, immunohistochemical analysis of the expression of PLCε, keratin 14 (K14), and keratin 1 (K1) in the PLCε+/+ mouse skin. Detection was performed with a fluorescein isothiocyanate-conjugated secondary antibody (B) or the HistoMouse Plus kit (C). Scale bars, 100 μm.

Fig. 2. Skin tumor formation. A, representative tumors developed in PLCε+/+ (+/+), PLCε+/− (+/−), and PLCε−/− (−/−) mice at 30 weeks after initiation. B, time course of tumor formation. The average number of tumors per mouse (average ± SE) is shown. C, size distribution of tumors at 20 weeks after initiation. D, photomicrographs of hematoxylin and eosin-stained sections of a representative SCC in a PLCε+/+ mouse (+/+) and a papilloma in a PLCε−/− mouse (−/−) at 30 weeks. The SCC exhibits tumor invasion (black arrow) and a cancer pearl with parakeratosis (white arrow). Scale bars, 1 mm.
Representative photomicrographs of at least three independent experiments are shown. Dermal hyperplasia was also suppressed in skin showed only a moderate increase (Fig. 3). TPA-induced epidermal hyperplasia was also suppressed in PLCe+/− mice (Fig. 3A). In striking contrast, PLCe−/− mouse skin showed only a moderate increase (Fig. 3A). TPA-induced epidermal hyperplasia was also suppressed in PLCe+/− mice (Fig. 3B). The average thickness of the epidermis after 48 hours of TPA treatment was 98.4, 66.3, and 31.3 μm in PLCe+/−, PLCe−/−, and PLCe−/− mice, respectively, whereas that after acetone treatment was 27.7, 25.4, and 24.6 μm, respectively. We have shown here that PLCe plays a crucial role in skin papilloma formation and malignant progression, which are induced by ras activation followed by TPA treatment. Furthermore, PLCe is shown to function downstream of TPA to induce hyperproliferation of the basal layer cells and skin hyperplasia. Thus, it is likely that PLCe functions in TPA-induced tumor promotion of the initiated cells carrying the activated ras genes. There are two possible mechanisms linking TPA to PLCe activation. TPA may activate PLCe through Ras activation, which is mediated by RasGRP1, a TPA-regulated Ras-specific guanine nucleotide exchange factor (GEF) expressed in keratinocytes (13). Rap1, whose activation is mediated by TPA-responsive Rap GEFs including CalDAG-GEFI (14) and RasGRP2 (15), may also be responsible for PLCe activation. Alternatively, TPA may activate PLCe through secretion of tumor necrosis factor (TNF)-α from keratinocytes (16) and subsequent TNF-α–induced Ras activation (17). TNF-α has been implicated in both two-stage skin carcinogenesis and TPA-induced skin hyperplasia (16).

Because targeted inactivation of protein kinase C (PKC) η resulted in enhancement of both papilloma formation and TPA-induced skin hyperplasia, TPA-induced down-regulation of PKCη is thought to play a crucial role in induction of these phenomena (18). In the present study, TPA treatment failed to compensate for the deficiency in papilloma formation and skin hyperplasia of PLCe−/− mice, although TPA is known to mimic diacylglycerol, a product of PLCe, in regulating PKCγ. The result indicates that the PLCe pathway has an intrinsic role in skin hyperplasia and carcinogenesis, which is independent of the PKCγ pathway. This intrinsic function may be mediated by another of its products, inositol 1,4,5-trisphosphate. On the other hand, activation of PLCe in DMBA-initiated cells, which must be induced by constitutively active Ras and produce diacylglycerol, could not substitute for TPA treatment in promoting papilloma formation. This suggests that TPA possesses another target that is also required for tumor promotion. In addition, papillomas developed in PLCe−/− mice failed to undergo malignant conversion. It was reported that prostaglandins are involved in skin tumor progression in addition to promotion (19) and play a key role in intestinal polyposis (20). Considering that arachidonic acid, a precursor of prostaglandins, can be produced from diacylglycerol, it is possible that the role of PLCe may be mediated through prostaglandin signaling.

Our present results have shown that PLCe plays a crucial role in ras oncogene-induced de novo carcinogenesis of skin epithelial cells. They also provide the first concrete evidence for the importance of the PLC signaling in carcinogenesis. This leads to the idea that specific inhibitors of PLCe may be useful for treatment and prevention of certain types of cancer.

Acknowledgments

We thank Dr. Atsu Aiba, Dr. Ushio Kikkawa, Dr. Makoto Tadano, Shuzo Ikuta, and Tadashi Murase for helpful discussion and Shuichi Matsuda for excellent technical assistance.

References

19. Chida K, Hara T, Hirai T, et al. Disruption of protein kinase C η results in enhancement of both papilloma formation and TPA-induced skin hyperplasia. TPA-induced down-regulation of PKCη is thought to play a crucial role in induction of these phenomena (18). In the present study, TPA treatment failed to compensate for the deficiency in...
Crucial Role of Phospholipase Cε in Chemical Carcinogen-Induced Skin Tumor Development

Yunfeng Bai, Hironori Edamatsu, Sakan Maeda, et al.


Updated version
Access the most recent version of this article at:
http://cancerres.aacrjournals.org/content/64/24/8808

Cited articles
This article cites 20 articles, 9 of which you can access for free at:
http://cancerres.aacrjournals.org/content/64/24/8808.full#ref-list-1

Citing articles
This article has been cited by 22 HighWire-hosted articles. Access the articles at:
http://cancerres.aacrjournals.org/content/64/24/8808.full#related-urls

E-mail alerts
Sign up to receive free email-alerts related to this article or journal.

Reprints and Subscriptions
To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.

Permissions
To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.